Evidence map›Paper›PMID 34344361›Full record

ArticleMalaria journal2021

Analysing the essential proteins set of Plasmodium falciparum PF3D7 for novel drug targets identification against malaria.

Fawad Ali, Hira Wali, Saadia Jan, Asad Zia, Muneeba Aslam, Imtiaz Ahmad, Sahib Gul Afridi, Sulaiman Shams, Asifullah Khan

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Stabilizing Plasmodium falciparum proteins for small molecule drug discovery.Protein science : a publication of the Protein Society · 2026
    Article
  3. Article
  4. Review
  5. Revisiting theNPJ drug discovery · 2025
    Article
  6. Review
  7. Proposition ofCombinatorial chemistry & high throughput screening · 2024
    Review
  8. Frontiers in pharmacology · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Fawad AliDepartment of Biochemistry, Abdul Wali Khan University Mardan, Mardan, 23200, Pakistan.
Hira WaliDepartment of Biochemistry, Abdul Wali Khan University Mardan, Mardan, 23200, Pakistan.
Saadia JanDepartment of Biochemistry, Abdul Wali Khan University Mardan, Mardan, 23200, Pakistan.
Asad ZiaDepartment of Biochemistry, Abdul Wali Khan University Mardan, Mardan, 23200, Pakistan.
Muneeba AslamDepartment of Biochemistry, Abdul Wali Khan University Mardan, Mardan, 23200, Pakistan.
Imtiaz AhmadDepartment of Biochemistry, Abdul Wali Khan University Mardan, Mardan, 23200, Pakistan.
Sahib Gul AfridiDepartment of Biochemistry, Abdul Wali Khan University Mardan, Mardan, 23200, Pakistan.
Sulaiman ShamsDepartment of Biochemistry, Abdul Wali Khan University Mardan, Mardan, 23200, Pakistan.
Asifullah KhanDepartment of Biochemistry, Abdul Wali Khan University Mardan, Mardan, 23200, Pakistan. asif@awkum.edu.pk.ORCID http://orcid.org/0000-0002-1444-4249
Abdul Wali Khan University Mardan · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlasmodium falciparum is an obligate intracellular parasite of humans that causes malaria. Falciparum malaria is a major public health threat to human life responsible for high mortality. Currently, the risk of multi-drug resistance of P. falciparum is rapidly increasing. There is a need to address new anti-malarial therapeutics strategies to combat the drug-resistance threat.

methodsThe P. falciparum essential proteins were retrieved from the recently published studies. These proteins were initially scanned against human host and its gut microbiome proteome sets by comparative proteomics analyses. The human host non-homologs essential proteins of P. falciparum were additionally analysed for druggability potential via in silico methods to possibly identify novel therapeutic targets. Finally, the PfAp4AH target was prioritized for pharmacophore modelling based virtual screening and molecular docking analyses to identify potent inhibitors from drug-like compounds databases.

resultsThe analyses identified six P. falciparum essential and human host non-homolog proteins that follow the key druggability features. These druggable targets have not been catalogued so far in the Drugbank repository. These prioritized proteins seem novel and promising drug targets against P. falciparum due to their key protein-protein interactions features in pathogen-specific biological pathways and to hold appropriate drug-like molecule binding pockets. The pharmacophore features based virtual screening of Pharmit resource predicted a lead compound i.e. MolPort-045-917-542 as a promising inhibitor of PfAp4AH among prioritized targets.

conclusionThe prioritized protein targets may worthy to test in malarial drug discovery programme to overcome the anti-malarial resistance issues. The in-vitro and in-vivo studies might be promising for additional validation of these prioritized lists of drug targets against malaria.

Indexed as

Drug Delivery SystemsDrug ResistanceHumansMalaria, FalciparumPlasmodium falciparumProtein ConformationProtein Interaction Domains and MotifsProtozoan ProteinsVirulence FactorsProtozoan ProteinsVirulence FactorsAnti-malarial therapeuticsComparative proteomicsMalariaPharmacophore modellingPlasmodium falciparum

Identifiers

PMID34344361
PMCPMC8336052
OpenAlexW3152914004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.